

# UBE2L3 (UbcH7) [GST-tagged]

## E2 – Ubiquitin Conjugating Enzyme

Alternate Names: E2-F1, EC 6.3.2.19, L-UBC, UbcH7, UbcM4, Ubiquitin conjugating enzyme  
E2-18 kDa UbcH7, Ubiquitin conjugating enzyme UbcH7

**Cat. No.** 62-0041-020  
**Lot. No.** 1399

**Quantity:** 20 µg  
**Storage:** -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

### Background

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including regulated and targeted proteosomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE2L3 is a member of the E2 conjugating enzyme family and cloning of the human gene was first described by Moynihan *et al.* (1998). Human UBE2L3 has been mapped to chromosome 22q11.2-q13.1 and shares 97% homology with the mouse homologue (Moynihan *et al.*, 1996; Moynihan *et al.*, 1998). UBE2L3 efficiently mediates the ubiquitylation of E6AP (Nuber *et al.*, 1996). A protein complex comprising UBE2L3, the E3 ligase Parkin and alpha synuclein (alpha-Sp22) has been identified in which the substrate alpha-Sp22 becomes polyubiquitylated in normal human brains and targeted for degradation. Loss of Parkin function causes pathologic accumulation of alpha-Sp22 in the brain which is associated with Parkinson's Disease (Shimura *et al.*, 2001). UBE2L3 acts with E6-associated protein (E6-AP) to synergistically enhance the transcriptional activity of the progesterone receptor (PR) and increase its interaction with the steroid receptor coactivator 1 (SRC-1) (Verma *et al.*, 2004). Binding of UBE2L3 to the amino-terminal domain of SMAD 7 stimulates E3 ligase Smurf activity via its HECT domain; recruitment of the complex to the TGFbeta receptor facilitates receptor degradation during TGFbeta signalling (Ogunjimi *et al.*, 2005). Changes in levels of UBE2L3 during the cell cycle regulate entrance into and progression through S phase. UBE2L3 levels decrease during S-phase but are restored in G2, it

Continued on page 2

### Physical Characteristics

**Species:** human

**Source:** *E. coli* expression

**Quantity:** 20 µg

**Concentration:** 1 mg/ml

**Formulation:** 50 mM HEPES pH 7.5,  
150 mM sodium chloride, 2 mM  
dithiothreitol, 10% glycerol

**Molecular Weight:** ~45 kDa

**Purity:** >85% by InstantBlue™ SDS-PAGE

**Stability/Storage:** 12 months at -70°C;  
aliquot as required

### Protein Sequence:


MSPILGYWKIKGLVQPTRLLEYLEEKYEEH  
LYERDEGDKWRNKKFELGLEFPNLPYYIDG  
VKLTQSMAIIRYIADKHNMLGGCPKER  
AEISMLEGAVLDIRYGVSRVIAYSKDFETLKVD  
FLSKLPEMLKMFEDRLCHKTYLNGDHTVHP  
DFMLYDALDVVLYMDPMCLDAFPKLVCFK  
KRIEAIPIQIDKYLKSSKYIAWPLQGQWQATF  
GGGDHPPKSDLEVLFOGPLGSMASRRML  
KELEEIRKCGMKNFRNIQVDEANLLTWQGLIVP  
DNPPYDKGAFRIEINFPAEYFPKPPKITFKTIYH  
PNIDEKGQVCLPVISAENWKPKATKTDQVIQS  
LIALVNDPQPEHPLRADLAAEYSKDRKKKFC  
NAEEFTKKGKRPVD

Tag (**bold text**): N-terminal glutathione-S-transferase (GST)  
Protease cleavage site: PreScission™ (LEVLFO▼GP)  
UBE2L3 (regular text): Start **bold italics** (amino acid  
residues 1-154)  
Accession number: AAH53368

### Quality Assurance

#### Purity:

4-12% gradient SDS-PAGE  
InstantBlue™ staining  
lane 1: MW markers  
lane 2: 1 µg GST-UBE2L3



#### Protein Identification:

Confirmed by mass spectrometry.

#### E2-Ubiquitin Thioester Loading Assay:

The activity of GST-UBE2L3 was validated by loading E1 UBE1 activated ubiquitin onto the active cysteine of the GST-UBE2L3 E2 enzyme via a transthiolation reaction. Incubation of the UBE1 and GST-UBE2L3 enzymes in the presence of ubiquitin and ATP at 30°C was compared at two time points, T<sub>0</sub> and T<sub>10</sub> minutes. Sensitivity of the ubiquitin/GST-UBE2L3 thioester bond to the reducing agent DTT was confirmed.



www.ubiquigent.com  
Dundee, Scotland, UK

#### ORDERS / SALES SUPPORT

**International:** +1-617-245-0003  
**US Toll-Free:** 1-888-4E1E2E3 (1-888-431-3233)  
**Email:** sales.support@ubiquigent.com

#### UK HQ and TECHNICAL SUPPORT

**International:** +44 (0) 1382 381147 (9AM-5PM UTC)  
**US/Canada:** +1-617-245-0020 (9AM-5PM UTC)  
**Email:** tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

# UBE2L3 (UbcH7) [GST-tagged]

## E2 – Ubiquitin Conjugating Enzyme

Alternate Names: E2-F1, EC 6.3.2.19, L-UBC, UbcH7, UbcM4, Ubiquitin conjugating enzyme  
E2-18 kDa UbcH7, Ubiquitin conjugating enzyme UbcH7

**Cat. No.** 62-0041-020

**Lot. No.** 1399

**Quantity:** 20 µg

**Storage:** -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



**CERTIFICATE OF ANALYSIS Page 2 of 2**

## Background

*Continued from page 1*

is thought progression into G2 occurs by UBE2L3 modulation of the intra-S phase checkpoint mediated by Chk1 (Whitcomb *et al.*, 2009).

### References:

Moynihan TP, Ardley HC, Leek JP, Thompson J, Brindle NS, Markham AF, Robinson PA (1996) Characterization of a human ubiquitin-conjugating enzyme gene UBE2L3. *Mamm Genome* **7**, 520-5.

Moynihan TP, Cole CG, Dunham I, O'Neil L, Markham AF, Robinson PA (1998) Fine-mapping, genomic organization, and transcript analysis of the human ubiquitin-conjugating enzyme gene UBE2L3. *Genomics* **51**, 124-7.

Nuber U, Schwarz S, Kaiser P, Schneider R, Scheffner M (1996) Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5. *J Biol Chem* **271**, 2795-800.

Ogunjimi AA, Briant DJ, et al. (2005) Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. *Mol Cell* **19**, 297-308.

Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. *Science* **293**, 263-9.

Verma S, Ismail A, Gao X, Fu G, Li X, O'Malley BW, Nawaz Z (2004) The ubiquitin-conjugating enzyme UbcH7 acts as a coactivator for steroid hormone receptors. *Mol Cell Biol* **24**, 8716-26.

Whitcomb EA, Dudek EJ, Liu Q, Taylor A (2009) Novel control of S phase of the cell cycle by ubiquitin-conjugating enzyme H7. *Mol Biol Cell* **20**, 1-9.



[www.ubiquigent.com](http://www.ubiquigent.com)  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

**International:** +1-617-245-0003  
**US Toll-Free:** 1-888-4E1E2E3 (1-888-431-3233)  
**Email:** [sales.support@ubiquigent.com](mailto:sales.support@ubiquigent.com)

### UK HQ and TECHNICAL SUPPORT

**International:** +44 (0) 1382 381147 (9AM-5PM UTC)  
**US/Canada:** +1-617-245-0020 (9AM-5PM UTC)  
**Email:** [tech.support@ubiquigent.com](mailto:tech.support@ubiquigent.com)

Email [services@ubiquigent.com](mailto:services@ubiquigent.com) for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

**Limited Terms of Use:** For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0